SPLICESCREENPD: for splicing-modifying factors for late onset Pompe Disease

Funded by the AFM TELETHON under the AFM Telethon Call 2018 programme. The project has awarded to the Molecular Pathology Group at ICGEB, headed by Emanuel Buratti.

SPLICESCREENPD figure
Schematic diagram of the project HTS approaches to find small molecules capable of rescuing GAA exon 2 inclusion and enzymatic functionality in patient fibroblasts

The project received EUR 30K funding in collaboration with Azienda Saniataria Universitaria Integrata di Udine.

The long-term aim of this Project will be to identify an innovative therapeutic solution for Pompe Disease (PD- OMIM# 232300, hereinafter PD). In the short term, specific aims of the  Project will be to complete a set of 3 high-throughput screening analysis to identify factors/molecules able to restore normal splicing of the lysosomal acid alpha glucosidase gene (GAA; E.C.3.2.1.20) exon 2 in the presence of the common c.-32-13T>G splicing mutation. Such screenings will be performed during the first year of the Project. To achieve our goal we will take advantage of two experimental models that have been optimised in our laboratory: the first model is based on a Fluorescent Reporter system that can be used to measure variations in GAA exon 2 inclusion, whilst the second model is based on optimizing the use of patient fibroblasts to perform a functional GAA enzyme activity analysis.

Duration: 2018-2019

Donor/funding programme:

AFM TELETHON

Partners:

Azienda Saniataria Universitaria Integrata di Udine